Toward a CRISPR-based mouse model of Vhl -deficient clear cell kidney cancer: Initial experience and lessons learned
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2408549121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Laura A Stransky und 32 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Disease Models, Animal, Kidney Neoplasms, Von Hippel-Lindau Tumor Suppressor Protein. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | NIH | National Cancer Institute (NCI), NCI NIH HHS, in part with Federal Funds from the National Cancer Institute, National Institutes of Health.
Abstract (Originalsprache)
CRISPR is revolutionizing the ability to do somatic gene editing in mice for the purpose of creating new cancer models. Inactivation of the VHL tumor suppressor gene is the signature initiating event in the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC). Such tumors are usually driven by the excessive HIF2 activity that arises when the VHL gene product, pVHL, is defective. Given the pressing need for a robust immunocompetent mouse model of human ccRCC, we directly injected adenovirus-associated viruses (AAVs) encoding sgRNAs against VHL and other known/suspected ccRCC tumor suppressor genes into the kidneys of C57BL/6 mice under conditions where Cas9 was under the control of one of two different kidney-specific promoters ( Cdh16 or Pax 8) to induce kidney tumors. An AAV targeting Vhl, Pbrm1, Keap1 , and Tsc1 reproducibly caused macroscopic ccRCCs that partially resembled human ccRCC tumors with respect to transcriptome and cell of origin and responded to a ccRCC standard-of-care agent, axitinib. Unfortunately, these tumors, like those produced by earlier genetically engineered mouse ccRCCs, are HIF2 independent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892.
- Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
- Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.
- Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02115.
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA 02142.
ORCID-Profile: Laura S Schmidt, Baktiar Karim, W Marston Linehan, William G Kaelin
Förderung
- HHS | NIH | National Cancer Institute (NCI)
- NCI NIH HHS
- in part with Federal Funds from the National Cancer Institute, National Institutes of Health
Zitieren
APA
Stransky, L. A., Gao, W., Schmidt, L. S., Bi, K., Ricketts, C. J., Ramesh, V., James, A., Difilippantonio, S., Ileva, L., Kalen, J. D., Karim, B., Jeon, A., Morgan, T., Warner, A. C., Turan, S., Unite, J., Tran, B., Choudhari, S., Zhao, Y., …, & Kaelin, W. G. (2024). Toward a CRISPR-based mouse model of Vhl -deficient clear cell kidney cancer: Initial experience and lessons learned. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2408549121
Vancouver
Stransky LA, Gao W, Schmidt LS, Bi K, Ricketts CJ, Ramesh V, et al. Toward a CRISPR-based mouse model of Vhl -deficient clear cell kidney cancer: Initial experience and lessons learned. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2408549121
BibTeX
@article{Stransky2024,
author = {Stransky, Laura A and Gao, Wenhua and Schmidt, Laura S and Bi, Kevin and Ricketts, Christopher J and Ramesh, Vijyendra and James, Amy and Difilippantonio, Simone and Ileva, Lilia and Kalen, Joseph D and Karim, Baktiar and Jeon, Albert and Morgan, Tamara and Warner, Andrew C and Turan, Sevilay and Unite, Joanne and Tran, Bao and Choudhari, Sulbha and Zhao, Yongmei and Linn, Douglas E and Yun, Changhong and Dhandapani, Sripriya and Parab, Vaishali and Pinheiro, Elaine M and Morris, Nicole and He, Lixia and Vigeant, Sean M and Pignon, Jean-Christophe and Sticco-Ivins, Maura and Signoretti, Sabina and Van Allen, Eliezer M and Linehan, W Marston and Kaelin, William G},
title = {Toward a CRISPR-based mouse model of Vhl -deficient clear cell kidney cancer: Initial experience and lessons learned},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2408549121}
}
EUVIMED